NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
- State
- Under way
- Phase
- Phase 2
- People
- 50 planned
- Started
- 24 Oct 2024
- Primary completion
- Mar 2027
- Arms
- BIIB122 225 mg
- Results
- None posted
- 19 Sep 2024: Trial registered
- 24 Oct 2024: Trial started